In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly ...

is an mRNA-based vaccine that sends signals to your cells to produce the same protein F that causes the immune reaction that fights against RSV. These vaccines are recommended and available for ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

From today, February 3, pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation ...

The company’s latest RSV vaccine is yet to show promising sales. This has weighed on MRNA stock, down 52% since early 2024. Even if we look at a slightly longer period, the changes in MRNA stock ...

A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

With the triad of respiratory viruses present in our day-to-day, it is recommended that individuals receive both COVID-19, flu, and occasionally RSV and MPox vaccinations. However, there is a common ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. MRNA has guided for 2025 revenues of $1.5B-$2.5B which doesn't seem to have ...

designed to protect against RSV and COVID-19. Beyond vaccines, pharma is looking to develop mRNA vaccines to treat diseases requiring protein expression, such as cancer. Cancer has proved to be a ...

The bill would implement a moratorium for a decade. “I am not against vaccination in any way,” the freshman lawmaker said.

Moderna (MRNA) cut its 2025 forecast by $1 billion ... "In 2024, we achieved $3 billion to 3.1 billion in product sales, approval of our RSV vaccine, and continued to adapt our COVID-19 business ...